3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
552
Colorectal Neoplasms
246
Neoplasms
232
Prostatic Neoplasms
221
Carcinoma, Non-Small-Cell Lung
196
Stomach Neoplasms
153
Leukemia, Myeloid, Acute
149
Carcinoma, Hepatocellular
147
Lung Neoplasms
137
Rectal Neoplasms
135
Multiple Myeloma
133
Nasopharyngeal Carcinoma
112
Colonic Neoplasms
106
Neoplasm Metastasis
100
Precursor Cell Lymphoblastic Leukemia-Lymphoma
86
Lymphoma
85
Uterine Cervical Neoplasms
83
Pancreatic Neoplasms
82
Lymphoma, Large B-Cell, Diffuse
79
Ovarian Neoplasms
78
Leukemia
78
Head and Neck Neoplasms
77
Esophageal Neoplasms
74
Lymphoma, Follicular
72
Brain Neoplasms
70
Squamous Cell Carcinoma of Head and Neck
65
Recurrence
64
Leukemia, Lymphocytic, Chronic, B-Cell
59
Lymphoma, Non-Hodgkin
58
Pain
56
Interventions
padeliporfin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
OTHER
×
Transitional Cell Cancer of Renal Pelvis and Ureter
×
Clear all
NCT04620239
2026-02-04
UCM301
Steba Biotech S.A.
Phase 3
Recruiting
100 enrolled